Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting Chat 3/29/2026
Similar Community Posts Join
5 / 160 resultscommunity Pelage to present PP405 Phase 2a clinical trial full results at an upcoming medical meeting - CMO Christina Weng says
Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.
community PP405 Phase 2a press release with early results
PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.
community Quote from Pelage (PP-405) Spokesperson...
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
community Realistically, how much PP405 will cost?
PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.
community PP405 is nothing but a scam and Pelage know it.
PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.
Related Research
6 / 855 resultsresearch Expression of Cyclooxygenase Isozymes During Morphogenesis and Cycling of Pelage Hair Follicles in Mouse Skin: Precocious Onset of the First Catagen Phase and Alopecia upon Cyclooxygenase-2 Overexpression
Overexpression of COX-2 causes early hair loss in mice, but can be prevented with a COX-2 inhibitor.
research The prostamide‐related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias
Bimatoprost, a glaucoma medication, may also help treat hair loss.
research The importance of basonuclin 2 in adult mice and its relation to basonuclin 1
Basonuclin 2 is vital for the development of facial bones, hair follicles, and male germ cells in adult mice, and its absence can lead to dwarfism and abnormal follicles.
research Expression Pattern of Cyclooxygenase-2 in Normal Rat Epidermis and Pilosebaceous Unit during Hair Cycle
COX-2 levels change during the hair cycle and affect skin and hair growth.
research Localisation of members of the notch system and the differentiation of vibrissa hair follicles: Receptors, ligands, and fringe modulators
Notch-related genes play a key role in the development and cycling of hair follicles.
research Androgen receptors are only present in mesenchyme-derived dermal papilla cells of red deer (Cervus elaphus) neck follicles when raised androgens induce a mane in the breeding season
Red deer only have androgen receptors in neck hair cells for mane growth during breeding season.